article · Pharmaceutical Development and Technology
murine infection model was established. Parasitological burden (oocyst shedding), biochemical markers (ALT and AST), immunological parameters (IFN-γ, TNF-α, IL-6, and IL-10), and TEM ultrastructure of intestinal tissues were assessed. BBR-SeNLCs demonstrated successful berberine encapsulation. Among treatments, BBR-SeNLCs achieved comparable antiparasitic effects, with a notable reduction in oocyst shedding relative to infected controls. Biochemical assays indicate formulation-dependent hepatoprotective trends, particularly in BBR-SeNLCs formulations. Immunologically, Se-containing groups (Se alone and BBR-SeNLCs) displayed a shift toward moderated inflammatory responses (reduced IFN-γ, TNF-α, IL-6) with preserved or enhanced anti-inflammatory IL-10, suggesting balanced host immunity. Parasitological and ultrastructural analyses corroborated these findings, with BBR-SeNLCs showing preserved intestinal architecture and reduced parasite burden in treated groups.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/10837450.2026.2620476
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.